Literature DB >> 15672302

[Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?].

G Stoppe1, O Pirk, M Haupt.   

Abstract

STUDY
OBJECTIVES: To practice evidence-based medicine is considered to improve health care, particularly of chronically ill patients. Taking Alzheimer's as an example the objective of this study is to explore as to how far ambulatory Alzheimer's patients receive the medical treatment with the best evidence available.
METHOD: In 2000 and 2002 the health care situation of Alzheimer's disease patients was assessed by conducting telephone interviews with one hundred randomly selected general practitioners and specialists listed in the panel of the Institut fur Medizinische Statistik (IMS -- Institute for Medical Statistics). By means of a standardised questionnaire the interviewees' prescriptions were assessed as well as their knowledge of the medical therapy for Alzheimer's and the use of non-medical therapeutic measures. Besides, the interviewees' prescriptions were checked on the basis of quantitative data taken from the IMS panel. Cholinesterase inhibitors (ChE-I), which are accorded the best evidence presently available in the medical treatment of Alzheimer's, were seen as a marker for the improvement of health care in the course of the study. RESULTS AND
CONCLUSIONS: The interviewed physicians considered the evidence of medical Alzheimer's disease therapy with cholinesterase inhibitors high. 67 % of the interviewees would use ChE-I as the drug of first choice if a near relative fell ill with Alzheimer's. However, the ChE-I prescriptions were limited to 13 % in the base year 2000 and to 24 % in the base year 2002. Obviously, the implementation of this medical therapy is hampered by budgetary regulations. The interviewees find it particularly disadvantageous that the prescription of ChE-I may overstrain the budgets allocated to their practices. As a consequence, the effort to improve the quality of health care by implementing evidence-based medicine is thwarted by the increasing pressure on German physicians to prescribe drugs according to economic viability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15672302     DOI: 10.1055/s-2004-813937

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  5 in total

Review 1.  [Questions and theses of pharmacological therapeutic options of Alzheimer's dementia with acetylcholinesterase inhibitors].

Authors:  H van den Bussche
Journal:  Z Gerontol Geriatr       Date:  2005-09       Impact factor: 1.281

2.  [The practice staff in primary care dementia recognition-is there an untapped potential?]

Authors:  Julian Wangler; Andreas Fellgiebel; Michael Jansky
Journal:  Z Gerontol Geriatr       Date:  2018-11-26       Impact factor: 1.281

3.  Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians.

Authors:  Elke Jeschke; Thomas Ostermann; Horst C Vollmar; Manuela Tabali; Friedemann Schad; Harald Matthes
Journal:  BMC Neurol       Date:  2011-08-08       Impact factor: 2.474

4.  Dementia diagnostics in general practitioner care : Do general practitioners have reservations? The findings of a qualitative study in Germany.

Authors:  Julian Wangler; Michael Jansky
Journal:  Wien Med Wochenschr       Date:  2019-12-06

5.  Factors influencing general practitioners' perception of and attitude towards dementia diagnostics and care-results of a survey among primary care physicians in Germany.

Authors:  Julian Wangler; Michael Jansky
Journal:  Wien Med Wochenschr       Date:  2021-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.